This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

4 Biotech Penny Stocks to Buy: Navellier

The following commentary comes from an independent investor or market observer as part of TheStreet's guest contributor program, which is separate from the company's news coverage.

NEW YORK ( InvestorPlace) -- Some of the hottest penny stocks to buy now are in the biotech sector. Start-ups and early-phase biotechnology companies can provide explosive profit potential for investors who are in on the ground floor of a game-changing medical technology or blockbuster drug.

That said, finding hot penny stocks in the biotech sector is no easy task. There are lots of micro-caps and pink sheet stocks out there that wreak havoc on the portfolios of penny stock investors. But buying penny stocks doesn't have to be an all-out gamble -- by screening for investments with a decent market cap ($100 million or more) and a listing on a major exchange, you can find ultracheap stocks that are very fast movers but considerably less risky.

Here are my favorite four biotech penny stocks to buy now:

YM BioSciences (YMI): The first stock on the list is biopharmaceutical company YM BioSciences, which develops products for the treatment of cancer. In the last 12 months, YMI stock has gained 63%. More recently, YMI is up 8% year to date and is trading near its 52-week high of $2.52.

Zalicus (ZLCS): Since the start of 2011, has watched its stock value rise 44%, compared with much smaller gains by the broader markets. This biopharmaceutical company, which focuses on the treatment of pain and inflammation, has experienced stock growth of 70% since last April. Buy this stock with a 52-week range of $1.01 to $2.72. Zalicus is one of InvestorPlace.com's 10 Best Stocks for 2011.

AEterna Zentaris (AEZS - Get Report): Drug development company AEterna Zentaris specializes in oncology and endocrine therapy. Since the start of 2011, this penny stock has raised its stock value 8%. Investors are even more thrilled to see 52-week growth of 87%.

  • Related Article:Why Gold Will Hit $5,000 Soon
  • Dynavax Technologies (DVAX - Get Report): Known for discovering and developing products for the prevention and treatment of infectious diseases, asthma and autoimmune diseases, Dynavax Technologies has gained 36% in the last six months. Going further back, this penny stock has shown impressive gains of 84% in the last year.

    As of this writing, Louis Navellier did not own a position in any of the stocks named here.

    One of Wall Street's renowned growth investors, Louis Navellier is the editor of four investing newsletters: Emerging Growth (formerly known as MPT Review), Blue Chip Growth, Quantum Growth and Global Growth. His longest-running publication, Emerging Growth, has a track record of beating the market nearly 3 to 1. Navellier is the author of a BusinessWeek bestseller, "The Little Book That Makes You Rich," and the chairman and founder of Navellier & Associates, Inc.

    Check Out Our Best Services for Investors

    Action Alerts PLUS

    Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

    Product Features:
    • $2.5+ million portfolio
    • Large-cap and dividend focus
    • Intraday trade alerts from Cramer
    Quant Ratings

    Access the tool that DOMINATES the Russell 2000 and the S&P 500.

    Product Features:
    • Buy, hold, or sell recommendations for over 4,300 stocks
    • Unlimited research reports on your favorite stocks
    • A custom stock screener
    Stocks Under $10

    David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

    Product Features:
    • Model portfolio
    • Stocks trading below $10
    • Intraday trade alerts
    14-Days Free
    Only $9.95
    14-Days Free
    Dividend Stock Advisor

    David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

    Product Features:
    • Diversified model portfolio of dividend stocks
    • Updates with exact steps to take - BUY, HOLD, SELL
    Trifecta Stocks

    Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

    Product Features:
    • Model Portfolio
    • Intra Day Trade alerts
    • Access to Quant Ratings
    Options Profits

    Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

    Product Features:
    • Actionable options commentary and news
    • Real-time trading community
    SYM TRADE IT LAST %CHG
    AEZS $0.30 -4.54%
    DVAX $21.74 -1.09%
    ZLCS $7.52 -2.46%
    AAPL $132.54 0.88%
    FB $80.54 0.07%

    Markets

    DOW 18,232.02 -53.72 -0.29%
    S&P 500 2,126.06 -4.76 -0.22%
    NASDAQ 5,089.3620 -1.4320 -0.03%

    Partners Compare Online Brokers

    Free Reports

    Top Rated Stocks Top Rated Funds Top Rated ETFs